Description
SLU-PP-322 is a research-grade experimental small molecule studied primarily in preclinical metabolic and exercise-mimetic research. It is not an approved medication and is not used in standard clinical practice.
Introduction
SLU-PP-322 is commonly referenced in scientific and commercial research catalogs as a synthetic metabolic regulator / exercise-mimetic compound. It is associated in literature and supplier documentation with the SLU-PP-332 family of compounds, which are estrogen-related receptor (ERR) agonists that influence cellular energy metabolism.
These compounds are investigated for their ability to modulate mitochondrial function, energy expenditure, and oxidative metabolism, particularly in skeletal muscle and other high-energy tissues.
SLU-PP-322 is typically supplied in lyophilized powder or vial form for laboratory research use only, with no established therapeutic indication in humans.
Scientific Classification (Tabulated Description)
| Parameter | Description |
|---|---|
| Compound Name | SLU-PP-322 |
| Related Name | SLU-PP-332 (commonly linked in supplier/literature contexts) |
| Compound Type | Experimental small molecule |
| Research Class | Metabolic / mitochondrial / exercise-mimetic agent |
| Target Pathway | Estrogen-related receptors (ERRα, ERRβ, ERRγ) |
| Primary Action (Research) | Modulation of mitochondrial biogenesis and oxidative metabolism |
| Mechanism Context | Activation of transcriptional pathways linked to PGC-1α signaling |
| Chemical Form | Lyophilized powder (research-grade preparations) |
| Appearance | White to off-white solid |
| Intended Use | Laboratory / in-vitro / preclinical research only |
| Clinical Approval | Not approved for human medical use |
| Storage Conditions | Typically -20°C, protected from light and moisture |
| Stability | Stable in dry (lyophilized) form under controlled storage |
Mechanism of Action (Research Findings)
Current preclinical studies on SLU-PP-322/332-class compounds suggest activity through estrogen-related receptor (ERR) activation, which regulates genes involved in energy metabolism.
Key pathways under investigation include:
- Activation of ERRα, ERRβ, ERRγ nuclear receptors
- Upregulation of PGC-1α signaling axis
- Increased transcription of genes involved in:
- Mitochondrial biogenesis
- Fatty acid oxidation
- Oxidative phosphorylation
- Enhanced cellular respiration in muscle tissue models
These effects are why SLU-PP-322 is often described as an “exercise-mimetic” research compound, meaning it mimics some molecular adaptations seen in endurance training at a cellular level (based on animal and in-vitro data).
Research Applications (Uses)
1. Metabolic Disease Research
SLU-PP-322 is studied in models of:
- Obesity
- Insulin resistance
- Metabolic syndrome
It is used to observe how mitochondrial activation influences energy balance.
2. Exercise Physiology Models
Researchers use it to investigate:
- Endurance adaptations
- Muscle fiber type shifts (oxidative vs glycolytic)
- Oxygen utilization efficiency
3. Mitochondrial Function Studies
It is widely used in laboratory settings to examine:
- Mitochondrial density changes
- ATP production efficiency
- Cellular respiration rates
4. Energy Expenditure Research
Preclinical work explores whether ERR activation may:
- Increase basal metabolic rate in animal models
- Influence thermogenesis pathways
- Alter lipid oxidation patterns
Advantages (Research Context Only)
1. Strong Mitochondrial Research Tool
SLU-PP-322 provides researchers with a controlled way to study mitochondrial biogenesis pathways.
2. Exercise-Mimetic Properties (Preclinical)
It helps model endurance-like metabolic changes without physical exercise intervention.
3. ERR Pathway Selectivity
Targets a central regulatory system involved in:
- Energy production
- Muscle adaptation
- Fat metabolism
4. Valuable for Comparative Studies
Frequently used alongside compounds like:
- AMPK activators
- PPAR agonists
- Other metabolic modulators
5. Useful in Multi-Pathway Research
Supports studies comparing:
- Mitochondrial signaling pathways
- Nuclear receptor activation networks
- Metabolic reprogramming in tissues
Important Research Note
SLU-PP-322 is considered experimental and preclinical:
- No approved human dosing exists
- No established medical indication
- Data is largely from cell and animal studies
- Safety profile in humans is not defined

Reviews
There are no reviews yet.